Baseline characteristics
| PID (N=6) | RTX (N=13) | csDMARD/bDMARD (N=31) | |
| Sex, n (%) | |||
| Female | 1 (17) | 12 (92) | 20 (65) |
| Male | 5 (83) | 1 (8%) | 11 (35%) |
| Mean age (years) (SD) | 42 (8.80) | 56 (14.50) | 53 (12.97) |
| Mean BMI (kg/m²) (SD) | 25 (5.45) | 30 (8.24) | 25 (5.72) |
| Smoking status, n (%) | |||
| Non-smoker | 3 (50) | 9 (69) | 12 (39) |
| Ex-smoker | 2 (33) | 4 (31) | 11 (35) |
| Smoker | 1 (17) | – | 8 (26) |
| Vaccination type for initial immunisation, n (%) | |||
| mRNA | 5 (83) | 10 (77) | 27 (87) |
| mRNA+vector | 1 (17) | – | 4 (13) |
| Vector | – | 2 (15) | – |
| Unknown | – | 1 (8) | – |
| Mean time from completed basic immunisation to BL (days) (SD) | 186 (33) | 176 (43) | 179 (27) |
| Underlying IMID, n (%) | |||
| Agammaglublinaemia | 1 (17) | – | – |
| CVID | 4 (67) | – | – |
| SCID | 1 (17) | – | – |
| Antisynthetase syndrome | – | 1 (8) | – |
| GPA | – | 5 (38) | – |
| Interstitial lung disease | – | 1 (8) | 1 (3) |
| MPA | – | 1 (8) | – |
| RA | – | 5 (38) | 6 (19) |
| axSpA | – | – | 2 (6) |
| Juvenile arthritis | – | – | 1 (3) |
| IgA vasculitis | – | – | 1 (3) |
| Adult-onset Still’s disease | – | – | 4 (13) |
| Polymyalgia rheumatica | – | – | 2 (6) |
| PsA | – | – | 9 (29) |
| Giant cell arteritis | – | – | 1 (3) |
| Sarcoidosis | – | – | 2 (6) |
| SLE | – | – | 1 (3) |
| Systemic sclerosis | – | – | 1 (3) |
| Ongoing immunotherapy | |||
| IgG intravenous | 4 (67) | – | – |
| IgG subcutaneous | 2 (33) | – | – |
| RTX | – | 13 (100) | – |
| csDMARD | – | 5 (38) | 14 (45) |
| Low-dose steroids (<10 mg/day) | – | 8 (61) | 9 (29) |
| High-dose steroids (≥10 mg/day) | – | – | 1 (3) |
| TNF inhibitors | – | – | 11 (35) |
| Abatacept | – | – | 4 (13) |
| IL-1 inhibitors | – | – | 4 (13) |
| IL-6 inhibitors | 1 (3) | ||
| IL-17 inhibitors | 4 (13) | ||
| IL-12/23 inhibitors | 3 (10) |
axSpA, axial spondyloarthritis; bDMARD, biological disease-modifying antirheumatic drug; BL, baseline; BMI, body mass index; csDMARD, conventional synthetic disease-modifying antirheumatic drug; CVID, common variable immunodeficiency; GPA, granulomatosis with polyangiitis; IL, interleukin; IMID, immune-mediated inflammatory disease; MPA, microscopic polyangiitis; PID, primary immunodeficiency; PsA, psoriatic arthritis; RA, rheumatoid arthritis; RTX, rituximab; SCID, severe combined immunodeficiency; SLE, systemic lupus erythematosus; TNF, tumour necrosis factor.